Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1996-2-22
|
pubmed:abstractText |
IL-1 is purported to be a proximal mediator in the cascade leading to septic shock. To characterize its hemodynamic effects and to ascertain whether its blockade would ameliorate the deleterious consequences of sepsis, an IL-1 receptor antagonist (IL-1ra) was administered to 16 anesthetized, mechanically ventilated piglets that received a continuous infusion of group B streptococci (GBS) (7.5 x 10(7) colony-forming units/kg/min). Systemic (Psa), pulmonary artery (Ppa), and wedge (Pwp) pressures and cardiac output were measured pre-GBS and every 30 min during GBS infusion. After 15 min of bacterial infusion the control group received normal saline, whereas the treatment group received a bolus of IL-1ra (40 mg/kg) followed by a continuous infusion of IL-1ra (60 micrograms/kg/min). In comparing IL-1ra-treated animals with controls from the 15-min GBS baseline to the succeeding septic study period (45-120 min), the following treatment effects were noted (120-min values shown): mean Psa remained elevated in treatment compared with control animals (12.7 +/- 2.5 versus 9 +/- 3.5 kPa; p < 0.001) as did CO (0.21 +/- 0.07 versus 0.13 +/- 0.08 L/min/kg; p < 0.001). Pwp decreased in the treatment compared to the control group over the study period (1 +/- 0.3 versus 1.6 +/- 0.7 kPa; p < 0.02). Mean Ppa and mean Pra were not different between groups over time. Median length of survival was significantly longer (p = 0.04) in treated (226 min) compared with control animals (150 min). These data suggest that IL-1 plays an important role in GBS sepsis and septic shock, and that IL-1ra may in part ameliorate the cardiovascular alterations associated with GBS sepsis in the neonate.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/IL1RN protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin 1 Receptor Antagonist...,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-1,
http://linkedlifedata.com/resource/pubmed/chemical/Sialoglycoproteins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0031-3998
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
38
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
704-8
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8552437-Animals,
pubmed-meshheading:8552437-Animals, Newborn,
pubmed-meshheading:8552437-Disease Models, Animal,
pubmed-meshheading:8552437-Hemodynamics,
pubmed-meshheading:8552437-Humans,
pubmed-meshheading:8552437-Interleukin 1 Receptor Antagonist Protein,
pubmed-meshheading:8552437-Receptors, Interleukin-1,
pubmed-meshheading:8552437-Sepsis,
pubmed-meshheading:8552437-Sialoglycoproteins,
pubmed-meshheading:8552437-Streptococcal Infections,
pubmed-meshheading:8552437-Streptococcus agalactiae,
pubmed-meshheading:8552437-Swine
|
pubmed:year |
1995
|
pubmed:articleTitle |
Effect of an interleukin-1 receptor antagonist on the hemodynamic manifestations of group B streptococcal sepsis.
|
pubmed:affiliation |
Department of Pediatrics, University of Miami School of Medicine, Florida 33101, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|